SPS
KRYS icon

Susquehanna Portfolio Strategies’s Krystal Biotech KRYS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Hold
4,104
– – 0.02% 628
2025
Q4 		$1.01M Buy
4,104
+325
+9% +$68.4K 0.02% 641
2025
Q3 		$667K Buy
3,779
+240
+7% +$35.9K 0.01% 761
2025
Q2 		$486K Buy
+3,539
New +$520K 0.01% 657

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Portfolio Strategies's KRYS Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Krystal Biotech (KRYS) position steady in Q1 2026 at 4,104 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #628.

Susquehanna Portfolio Strategies first reported a position in KRYS in Q2 2025 and has held it in 4 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Susquehanna Portfolio Strategies held 4,104 shares of Krystal Biotech worth $1.06M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #628 holding.
  • Susquehanna Portfolio Strategies first reported a position in Krystal Biotech in Q2 2025 and has held it in 4 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.